Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURANEST vs ALCAINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Etonidate is an ultrashort-acting nonbarbiturate hypnotic agent that produces anesthesia by enhancing GABA-mediated chloride conductance at GABA-A receptors, leading to central nervous system depression.
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.
Induction of general anesthesia,Supplementation of subpotent anesthetic agents (off-label),Procedural sedation (off-label)
Ophthalmic anesthesia for procedures such as cataract extraction, tonometry, gonioscopy, and suture removal
2-10 m L of a 1-2% solution, subarachnoid injection, single dose only.
1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.
Terminal elimination half-life is 4.5 hours (range 3-6 hours). Clinical context: Prolonged in severe hepatic impairment but not significantly in renal impairment.
Terminal elimination half-life: 0.4–1.2 minutes (rapid enzymatic hydrolysis by plasma esterases); clinical significance: ultra-short duration limits systemic toxicity.
Primarily hepatic via hydrolysis by esterases (plasma and hepatic) to inactive metabolites. Less than 5% excreted unchanged in urine.
Hydrolyzed by plasma esterases.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% unchanged drug. Biliary/fecal elimination is minimal.
Renal excretion of parent drug and metabolites: <5% unchanged.
85-90% bound primarily to alpha-1-acid glycoprotein; minor binding to albumin.
Minimal; <5% bound to plasma proteins.
Vd is 2.5-3.5 L/kg, indicating extensive extravascular distribution and tissue binding.
Not clinically meaningful due to rapid hydrolysis; Vd estimated <0.5 L/kg (low, consistent with high water solubility and rapid clearance).
Oral: 60-70% (first-pass metabolism); Intramuscular: ~90%; Intravenous: 100%.
Ophthalmic topical: negligible systemic absorption (minimal bioavailability); not applicable systemically.
No specific guidelines; contraindicated in severe renal impairment due to potential for accumulation of preservatives.
No dose adjustment required; negligible systemic absorption.
Use with caution; no specific Child-Pugh adjustments available. Contraindicated in severe hepatic disease due to impaired metabolism.
No dose adjustment required; negligible systemic absorption.
Not recommended for pediatric use due to limited data and high risk of neurotoxicity.
1 drop of 0.5% solution topically to the eye, repeated as needed; maximum 1 drop per dose in infants and young children to avoid systemic effects.
Reduce dose and volume; monitor for prolonged motor block and hypotension. Use lowest effective dose.
No specific adjustment; use lowest effective dose due to potential increased corneal sensitivity and delayed healing.
None.
Not for injection or prolonged use; corneal toxicity with repeated or prolonged use.
Adrenocortical suppression: Etonidate inhibits 11β-hydroxylase, reducing cortisol and aldosterone synthesis; may last up to 24 hours after single dose.,Myoclonus: Involuntary muscle movements occur in up to 70% of patients, especially with rapid injection.,Hypotension: Less pronounced than with other induction agents, but may occur, particularly in hypovolemic patients.,Injection site pain: Common with peripheral administration.,Use in intensive care: Prolonged infusion associated with increased mortality; not recommended for sedation in ICU.,Pregnancy category C: Use only if clearly needed.
Prolonged use may cause corneal epithelial damage and delay wound healing. Avoid contamination of the dropper tip.
Hypersensitivity to etonidate or any component of the formulation,Use as sole anesthetic agent for major surgery without adequate muscle relaxation or intubation,Acute porphyria (relative contraindication)
Hypersensitivity to any component of the formulation.
No known direct food interactions. However, avoid hot beverages and foods until numbness resolves to prevent oral burns. No specific dietary restrictions.
None known.
Duranest (etidocaine) is a local anesthetic of the amide type. Limited human data; animal studies show no teratogenicity at clinically relevant doses. Use in first trimester only if clearly needed. Second and third trimesters: no known teratogenic risk; may cause fetal bradycardia if high systemic levels occur. Avoid in near-term unless necessary due to neonatal effects.
Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenic effects at doses up to 0.5 mg/kg (SC). Potential fetal risk unlikely to exceed background risk. No known trimester-specific risks.
Excreted in breast milk in low concentrations; M/P ratio not established. Expected milk levels are minimal after regional anesthesia. Use with caution; monitor infant for signs of local anesthetic toxicity (irritability, drowsiness). Instruct mother to discard milk for 4 hours after injection if concerned.
Proparacaine is excreted into breast milk in unknown amounts, but due to minimal systemic absorption, the expected dose to infant is negligible. Manufacturer advises caution. No M/P ratio available.
No standard dose adjustments required for pregnancy per se. However, due to increased epidural venous plexus engorgement and decreased volume of distribution in the epidural space, reduce dose by 20-30% for epidural anesthesia to avoid unintended high block. Use lowest effective dose to minimize maternal and fetal exposure.
No dosing adjustment required for topical ophthalmic use due to negligible systemic absorption and lack of pharmacokinetic alterations in pregnancy.
DURANEST (articaine HCl 4% with epinephrine 1:100,000 or 1:200,000) is an amide local anesthetic commonly used in dentistry. Not effective for topical anesthesia; must be injected. Onset is rapid (1-3 min) with duration of pulpal anesthesia ~60-75 min and soft tissue anesthesia ~2-4 h. Maximum dose: 7 mg/kg (epinephrine 1:100,000) or 5 mg/kg (epinephrine 1:200,000). Avoid in patients with sulfite allergy (epinephrine component) or para-aminobenzoic acid (PABA) hypersensitivity. Caution in patients with methemoglobinemia (can cause methemoglobin formation at high doses).
ALCAINE (proparacaine) is a topical ophthalmic anesthetic. Onset within 20 seconds, duration ~15 minutes. Do not dispense for home use due to risk of corneal toxicity with prolonged use. Use a sterile, single-dose vial to prevent contamination. Monitor for stinging or burning on instillation. Avoid in patients with sulfite allergy (contains sodium bisulfite).
Avoid eating or drinking until numbness in mouth and throat has fully resolved (usually 2-4 hours) to prevent accidental biting or burns.,Do not chew gum or eat hard foods while numb.,Report any signs of allergic reaction (rash, hives, swelling, difficulty breathing) or prolonged numbness (>8 hours) to your dentist immediately.,Inform your dentist of all medications you are taking, especially MAO inhibitors, tricyclic antidepressants, beta-blockers, and anticoagulants.,If you have a history of sulfite sensitivity, tell your dentist before the procedure.
Temporary stinging or burning may occur upon application.,Do not touch the dropper tip to any surface to avoid contamination.,Do not use for more than instructed; prolonged use can damage the cornea.,Remove contact lenses before use and wait at least 15 minutes before reinserting.,Notify your doctor if you have a sulfite allergy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURANEST vs ALCAINE, answered by our medical review team.
DURANEST is a Local Anesthetic that works by Etonidate is an ultrashort-acting nonbarbiturate hypnotic agent that produces anesthesia by enhancing GABA-mediated chloride conductance at GABA-A receptors, leading to central nervous system depression.. ALCAINE is a Local Anesthetic that works by Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURANEST and ALCAINE depend on the specific clinical indication. These are both Local Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURANEST is: 2-10 m L of a 1-2% solution, subarachnoid injection, single dose only.. The standard adult dose of ALCAINE is: 1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURANEST and ALCAINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURANEST is classified as Category C. Duranest (etidocaine) is a local anesthetic of the amide type. Limited human data; animal studies show no teratogenicity at clinically relevant doses. Use in first trimester only i. ALCAINE is classified as Category C. Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant wom. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.